The addition of pertuzumab to a trastuzumab-docetaxel regimen in the neoadjuvant setting improved total pathological complete response (tpCR) rates in Asian women with early or locally advanced ERBB2-positive breast cancer, according to the phase III PEONY trial from China.
Oral antibiotic treatment for 3 months does not provide a clinically important benefit to patients with chronic low back pain, previous disc herniation and vertebral endplate (Modic) changes as compared with placebo, according to a Norway study.
Use of a polypill or fixed-dose combination of aspirin, atorvastatin, hydrochlorothiazide and enalapril appears to effectively cut the risk of major cardiovascular events, with high adherence and low adverse event (AE) rates, in individuals aged 50–75 years in a real-life setting, according to data from the PolyIran trial.
While effectiveness is generally comparable among the four first-line antihypertensive drug classes, initiating thiazides may be better than the most commonly prescribed class of ACE* inhibitors in reducing primary cardiovascular (CV) outcomes, suggests real-world evidence from the LEGEND-HTN** study.
The osteoporosis medications teriparatide, romosozumab, raloxifene and denosumab all confer significant benefits for reducing vertebral and hip fractures and inducing changes in bone mineral density at the femoral neck as compared with placebo, according to the results of a network meta-analysis.
The addition of the fluoroquinolone levofloxacin to myeloma therapy during the first 12 weeks led to a significant reduction in febrile episodes and deaths compared with placebo, suggesting that levofloxacin prophylaxis could be a standard of care in the first 3 months following myeloma diagnosis to prevent infection, according to a British study.
Children with familial hypercholesterolemia (FH) who receive statin therapy in childhood could potentially delay the progression of carotid intima-media thickness and reduce their risk of cardiovascular (CV) disease (CVD) in adulthood, according to a long-term follow-up study.
Nonvitamin K antagonist oral anticoagulants (NOACs) appear to confer more clinical benefits to elderly patients with atrial fibrillation (AF) than vitamin K antagonist anticoagulants (VKAs), suggests a study, adding that this is primarily driven by the lower rates of major bleeding.
Multiple intralesional injections with purified protein derivative (PPD) leads to faster clearance of common warts compared with a single injection, although the latter is better tolerated, as shown in the results of an open‐label, superiority trial.
Use of direct acting antivirals (DAAs) to treat hepatitis C virus (HCV) infection is feasible during pregnancy, as these drugs are highly effective and treatment duration is relatively short, according to a study. In addition, DAA treatment helps improve maternal health and prevent vertical transmission.